Global DTaP Vaccine  Market
Global DTaP Vaccine  Market

DTaP Vaccine  Comprehensive Study by Type (Diphtheria, Tetanus, Pertussis), Application (Adult, Pediatric), Product Type (Generic Drug, Branded Drug), End User (Hospitals, Clinics, Vaccination Centers) Players and Region - Global Market Outlook to 2026

DTaP Vaccine  Market Segmented into XX Submarkets. | Forecast Years: 2021- 2026  

Apr 2021 Edition 200 Pages 216 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Global DTaP Vaccine  Market Overview:
DTaP (Diphtheria-Tetanus-acellular Pertussis) vaccine is a combination immunizing agent given by injection to protect against infections caused by diphtheria, tetanus (lockjaw), and pertussis (whooping cough). Diphtheria and tetanus (DT) vaccine is given to children and combined tetanus, diphtheria and acellular pertussis (Tdap) vaccine is given to adolescents and adults. As per sources, in 2017, DTaP vaccine sales value in china was ~27 Million USD. In 2018, ~151 000 cases of pertussis were registered globally. In addition, 86% of the global target population received the recommended three doses of DTP-containing vaccine during infancy in 2018. The rising government and non-government initiatives for vaccine development are expected to offer lucrative opportunities for market growth in the estimated forecast period.

Growth Drivers
  • Introduction Of Combination Vaccines
  • Enhancement Of Vaccine Development Technology

Market Trends
  • Increasing Incidences Of Diphtheria, Tetanus And Pertussis

Roadblocks
  • Reactions Such As Seizure Or High Fever in Children

Opportunities
  • Favorable R&D Scenario
  • Demand For D&T Containing Vaccines
  • Growing Efforts By Global Organizations To Promote Immunization Programs

Challenges
  • Strict Regulation & Longer Timeline Required To Produce Vaccines


Competitive Landscape:
The providers in the global DTaP vaccine market continue to focus on innovation and updation in their products. Such developments coupled with competitive pricing are likely to assist in increasing market share over the forecast period. The key players are investing heavily in research & development to enhance their product effectiveness on treating diphtheria, tetanus & pertussis diseases to maintain their market presence in altering consumer buying preferences.
Some of the key players profiled in the report are GlaxoSmithKline plc (United Kingdom), Sanofi (France), Novartis International AG (Switzerland), Merck (Germany), Pfizer Inc. (United States), Astellas Pharma Inc. (United States), Emergent BioSolutions Inc. (United States), AstraZeneca plc (United Kingdom), Serum Institute Of India (India) and Grifols, S.A.(Spain). Considering Market by Product Type, the sub-segment i.e. Generic Drug will boost the DTaP Vaccine  market. Considering Market by End User, the sub-segment i.e. Hospitals will boost the DTaP Vaccine  market.

In September 2020, Sanofi’s part Sanofi Pasteur India launched Tetraxim (DTaP-IPV) vaccine. This vaccine is indicated for preschoolers and provides protection against four major diseases that includes Diphtheria, Pertussis, Tetanus and Polio.

Available Customization:
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be provided prior to purchase

Research Methodology:
The top-down and bottom-up approaches are used to estimate and validate the size of the Global DTaP Vaccine  market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in DTaP Vaccine  market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes New Entrants/Investors, Analysts and Strategic Business Planners, DTaP Vaccine Manufacturer, Raw Material Suppliers, Traders and Distributors, Venture Capitalists and Private Equity Firms, Government Regulatory and Research Organizations and End Use Industry.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.
Report Objectives / Segmentation Covered
By Type
  • Diphtheria
  • Tetanus
  • Pertussis
By Application
  • Adult
  • Pediatric
By Product Type
  • Generic Drug
  • Branded Drug

By End User
  • Hospitals
  • Clinics
  • Vaccination Centers

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Introduction Of Combination Vaccines
      • 3.2.2. Enhancement Of Vaccine Development Technology
    • 3.3. Market Challenges
      • 3.3.1. Strict Regulation & Longer Timeline Required To Produce Vaccines
    • 3.4. Market Trends
      • 3.4.1. Increasing Incidences Of Diphtheria, Tetanus And Pertussis
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global DTaP Vaccine , by Type, Application, Product Type, End User and Region (value) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global DTaP Vaccine  (Value)
      • 5.2.1. Global DTaP Vaccine  by: Type (Value)
        • 5.2.1.1. Diphtheria
        • 5.2.1.2. Tetanus
        • 5.2.1.3. Pertussis
      • 5.2.2. Global DTaP Vaccine  by: Application (Value)
        • 5.2.2.1. Adult
        • 5.2.2.2. Pediatric
      • 5.2.3. Global DTaP Vaccine  by: Type (Value)
        • 5.2.3.1. Diphtheria
        • 5.2.3.2. Tetanus
        • 5.2.3.3. Pertussis
      • 5.2.4. Global DTaP Vaccine  by: Product Type (Value)
        • 5.2.4.1. Generic Drug
        • 5.2.4.2. Branded Drug
      • 5.2.5. Global DTaP Vaccine  by: End User (Value)
        • 5.2.5.1. Hospitals
        • 5.2.5.2. Clinics
        • 5.2.5.3. Vaccination Centers
      • 5.2.6. Global DTaP Vaccine  Region
        • 5.2.6.1. South America
          • 5.2.6.1.1. Brazil
          • 5.2.6.1.2. Argentina
          • 5.2.6.1.3. Rest of South America
        • 5.2.6.2. Asia Pacific
          • 5.2.6.2.1. China
          • 5.2.6.2.2. Japan
          • 5.2.6.2.3. India
          • 5.2.6.2.4. South Korea
          • 5.2.6.2.5. Taiwan
          • 5.2.6.2.6. Australia
          • 5.2.6.2.7. Rest of Asia-Pacific
        • 5.2.6.3. Europe
          • 5.2.6.3.1. Germany
          • 5.2.6.3.2. France
          • 5.2.6.3.3. Italy
          • 5.2.6.3.4. United Kingdom
          • 5.2.6.3.5. Netherlands
          • 5.2.6.3.6. Rest of Europe
        • 5.2.6.4. MEA
          • 5.2.6.4.1. Middle East
          • 5.2.6.4.2. Africa
        • 5.2.6.5. North America
          • 5.2.6.5.1. United States
          • 5.2.6.5.2. Canada
          • 5.2.6.5.3. Mexico
  • 6. DTaP Vaccine : Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. GlaxoSmithKline plc (United Kingdom)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Sanofi (France)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Novartis International AG (Switzerland)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Merck (Germany)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Pfizer Inc. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Astellas Pharma Inc. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Emergent BioSolutions Inc. (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. AstraZeneca plc (United Kingdom)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Serum Institute Of India (India)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Grifols, S.A.(Spain)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global DTaP Vaccine  Sale, by Type, Application, Product Type, End User and Region (value) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global DTaP Vaccine  (Value)
      • 7.2.1. Global DTaP Vaccine  by: Type (Value)
        • 7.2.1.1. Diphtheria
        • 7.2.1.2. Tetanus
        • 7.2.1.3. Pertussis
      • 7.2.2. Global DTaP Vaccine  by: Application (Value)
        • 7.2.2.1. Adult
        • 7.2.2.2. Pediatric
      • 7.2.3. Global DTaP Vaccine  by: Type (Value)
        • 7.2.3.1. Diphtheria
        • 7.2.3.2. Tetanus
        • 7.2.3.3. Pertussis
      • 7.2.4. Global DTaP Vaccine  by: Product Type (Value)
        • 7.2.4.1. Generic Drug
        • 7.2.4.2. Branded Drug
      • 7.2.5. Global DTaP Vaccine  by: End User (Value)
        • 7.2.5.1. Hospitals
        • 7.2.5.2. Clinics
        • 7.2.5.3. Vaccination Centers
      • 7.2.6. Global DTaP Vaccine  Region
        • 7.2.6.1. South America
          • 7.2.6.1.1. Brazil
          • 7.2.6.1.2. Argentina
          • 7.2.6.1.3. Rest of South America
        • 7.2.6.2. Asia Pacific
          • 7.2.6.2.1. China
          • 7.2.6.2.2. Japan
          • 7.2.6.2.3. India
          • 7.2.6.2.4. South Korea
          • 7.2.6.2.5. Taiwan
          • 7.2.6.2.6. Australia
          • 7.2.6.2.7. Rest of Asia-Pacific
        • 7.2.6.3. Europe
          • 7.2.6.3.1. Germany
          • 7.2.6.3.2. France
          • 7.2.6.3.3. Italy
          • 7.2.6.3.4. United Kingdom
          • 7.2.6.3.5. Netherlands
          • 7.2.6.3.6. Rest of Europe
        • 7.2.6.4. MEA
          • 7.2.6.4.1. Middle East
          • 7.2.6.4.2. Africa
        • 7.2.6.5. North America
          • 7.2.6.5.1. United States
          • 7.2.6.5.2. Canada
          • 7.2.6.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. DTaP Vaccine : by Type(USD Million)
  • Table 2. DTaP Vaccine  Diphtheria , by Region USD Million (2015-2020)
  • Table 3. DTaP Vaccine  Tetanus , by Region USD Million (2015-2020)
  • Table 4. DTaP Vaccine  Pertussis , by Region USD Million (2015-2020)
  • Table 5. DTaP Vaccine : by Application(USD Million)
  • Table 6. DTaP Vaccine  Adult , by Region USD Million (2015-2020)
  • Table 7. DTaP Vaccine  Pediatric , by Region USD Million (2015-2020)
  • Table 8. DTaP Vaccine : by Type(USD Million)
  • Table 9. DTaP Vaccine  Diphtheria , by Region USD Million (2015-2020)
  • Table 10. DTaP Vaccine  Tetanus , by Region USD Million (2015-2020)
  • Table 11. DTaP Vaccine  Pertussis , by Region USD Million (2015-2020)
  • Table 12. DTaP Vaccine : by Product Type(USD Million)
  • Table 13. DTaP Vaccine  Generic Drug , by Region USD Million (2015-2020)
  • Table 14. DTaP Vaccine  Branded Drug , by Region USD Million (2015-2020)
  • Table 15. DTaP Vaccine : by End User(USD Million)
  • Table 16. DTaP Vaccine  Hospitals , by Region USD Million (2015-2020)
  • Table 17. DTaP Vaccine  Clinics , by Region USD Million (2015-2020)
  • Table 18. DTaP Vaccine  Vaccination Centers , by Region USD Million (2015-2020)
  • Table 19. South America DTaP Vaccine , by Country USD Million (2015-2020)
  • Table 20. South America DTaP Vaccine , by Type USD Million (2015-2020)
  • Table 21. South America DTaP Vaccine , by Application USD Million (2015-2020)
  • Table 22. South America DTaP Vaccine , by Product Type USD Million (2015-2020)
  • Table 23. South America DTaP Vaccine , by End User USD Million (2015-2020)
  • Table 24. Brazil DTaP Vaccine , by Type USD Million (2015-2020)
  • Table 25. Brazil DTaP Vaccine , by Application USD Million (2015-2020)
  • Table 26. Brazil DTaP Vaccine , by Product Type USD Million (2015-2020)
  • Table 27. Brazil DTaP Vaccine , by End User USD Million (2015-2020)
  • Table 28. Argentina DTaP Vaccine , by Type USD Million (2015-2020)
  • Table 29. Argentina DTaP Vaccine , by Application USD Million (2015-2020)
  • Table 30. Argentina DTaP Vaccine , by Product Type USD Million (2015-2020)
  • Table 31. Argentina DTaP Vaccine , by End User USD Million (2015-2020)
  • Table 32. Rest of South America DTaP Vaccine , by Type USD Million (2015-2020)
  • Table 33. Rest of South America DTaP Vaccine , by Application USD Million (2015-2020)
  • Table 34. Rest of South America DTaP Vaccine , by Product Type USD Million (2015-2020)
  • Table 35. Rest of South America DTaP Vaccine , by End User USD Million (2015-2020)
  • Table 36. Asia Pacific DTaP Vaccine , by Country USD Million (2015-2020)
  • Table 37. Asia Pacific DTaP Vaccine , by Type USD Million (2015-2020)
  • Table 38. Asia Pacific DTaP Vaccine , by Application USD Million (2015-2020)
  • Table 39. Asia Pacific DTaP Vaccine , by Product Type USD Million (2015-2020)
  • Table 40. Asia Pacific DTaP Vaccine , by End User USD Million (2015-2020)
  • Table 41. China DTaP Vaccine , by Type USD Million (2015-2020)
  • Table 42. China DTaP Vaccine , by Application USD Million (2015-2020)
  • Table 43. China DTaP Vaccine , by Product Type USD Million (2015-2020)
  • Table 44. China DTaP Vaccine , by End User USD Million (2015-2020)
  • Table 45. Japan DTaP Vaccine , by Type USD Million (2015-2020)
  • Table 46. Japan DTaP Vaccine , by Application USD Million (2015-2020)
  • Table 47. Japan DTaP Vaccine , by Product Type USD Million (2015-2020)
  • Table 48. Japan DTaP Vaccine , by End User USD Million (2015-2020)
  • Table 49. India DTaP Vaccine , by Type USD Million (2015-2020)
  • Table 50. India DTaP Vaccine , by Application USD Million (2015-2020)
  • Table 51. India DTaP Vaccine , by Product Type USD Million (2015-2020)
  • Table 52. India DTaP Vaccine , by End User USD Million (2015-2020)
  • Table 53. South Korea DTaP Vaccine , by Type USD Million (2015-2020)
  • Table 54. South Korea DTaP Vaccine , by Application USD Million (2015-2020)
  • Table 55. South Korea DTaP Vaccine , by Product Type USD Million (2015-2020)
  • Table 56. South Korea DTaP Vaccine , by End User USD Million (2015-2020)
  • Table 57. Taiwan DTaP Vaccine , by Type USD Million (2015-2020)
  • Table 58. Taiwan DTaP Vaccine , by Application USD Million (2015-2020)
  • Table 59. Taiwan DTaP Vaccine , by Product Type USD Million (2015-2020)
  • Table 60. Taiwan DTaP Vaccine , by End User USD Million (2015-2020)
  • Table 61. Australia DTaP Vaccine , by Type USD Million (2015-2020)
  • Table 62. Australia DTaP Vaccine , by Application USD Million (2015-2020)
  • Table 63. Australia DTaP Vaccine , by Product Type USD Million (2015-2020)
  • Table 64. Australia DTaP Vaccine , by End User USD Million (2015-2020)
  • Table 65. Rest of Asia-Pacific DTaP Vaccine , by Type USD Million (2015-2020)
  • Table 66. Rest of Asia-Pacific DTaP Vaccine , by Application USD Million (2015-2020)
  • Table 67. Rest of Asia-Pacific DTaP Vaccine , by Product Type USD Million (2015-2020)
  • Table 68. Rest of Asia-Pacific DTaP Vaccine , by End User USD Million (2015-2020)
  • Table 69. Europe DTaP Vaccine , by Country USD Million (2015-2020)
  • Table 70. Europe DTaP Vaccine , by Type USD Million (2015-2020)
  • Table 71. Europe DTaP Vaccine , by Application USD Million (2015-2020)
  • Table 72. Europe DTaP Vaccine , by Product Type USD Million (2015-2020)
  • Table 73. Europe DTaP Vaccine , by End User USD Million (2015-2020)
  • Table 74. Germany DTaP Vaccine , by Type USD Million (2015-2020)
  • Table 75. Germany DTaP Vaccine , by Application USD Million (2015-2020)
  • Table 76. Germany DTaP Vaccine , by Product Type USD Million (2015-2020)
  • Table 77. Germany DTaP Vaccine , by End User USD Million (2015-2020)
  • Table 78. France DTaP Vaccine , by Type USD Million (2015-2020)
  • Table 79. France DTaP Vaccine , by Application USD Million (2015-2020)
  • Table 80. France DTaP Vaccine , by Product Type USD Million (2015-2020)
  • Table 81. France DTaP Vaccine , by End User USD Million (2015-2020)
  • Table 82. Italy DTaP Vaccine , by Type USD Million (2015-2020)
  • Table 83. Italy DTaP Vaccine , by Application USD Million (2015-2020)
  • Table 84. Italy DTaP Vaccine , by Product Type USD Million (2015-2020)
  • Table 85. Italy DTaP Vaccine , by End User USD Million (2015-2020)
  • Table 86. United Kingdom DTaP Vaccine , by Type USD Million (2015-2020)
  • Table 87. United Kingdom DTaP Vaccine , by Application USD Million (2015-2020)
  • Table 88. United Kingdom DTaP Vaccine , by Product Type USD Million (2015-2020)
  • Table 89. United Kingdom DTaP Vaccine , by End User USD Million (2015-2020)
  • Table 90. Netherlands DTaP Vaccine , by Type USD Million (2015-2020)
  • Table 91. Netherlands DTaP Vaccine , by Application USD Million (2015-2020)
  • Table 92. Netherlands DTaP Vaccine , by Product Type USD Million (2015-2020)
  • Table 93. Netherlands DTaP Vaccine , by End User USD Million (2015-2020)
  • Table 94. Rest of Europe DTaP Vaccine , by Type USD Million (2015-2020)
  • Table 95. Rest of Europe DTaP Vaccine , by Application USD Million (2015-2020)
  • Table 96. Rest of Europe DTaP Vaccine , by Product Type USD Million (2015-2020)
  • Table 97. Rest of Europe DTaP Vaccine , by End User USD Million (2015-2020)
  • Table 98. MEA DTaP Vaccine , by Country USD Million (2015-2020)
  • Table 99. MEA DTaP Vaccine , by Type USD Million (2015-2020)
  • Table 100. MEA DTaP Vaccine , by Application USD Million (2015-2020)
  • Table 101. MEA DTaP Vaccine , by Product Type USD Million (2015-2020)
  • Table 102. MEA DTaP Vaccine , by End User USD Million (2015-2020)
  • Table 103. Middle East DTaP Vaccine , by Type USD Million (2015-2020)
  • Table 104. Middle East DTaP Vaccine , by Application USD Million (2015-2020)
  • Table 105. Middle East DTaP Vaccine , by Product Type USD Million (2015-2020)
  • Table 106. Middle East DTaP Vaccine , by End User USD Million (2015-2020)
  • Table 107. Africa DTaP Vaccine , by Type USD Million (2015-2020)
  • Table 108. Africa DTaP Vaccine , by Application USD Million (2015-2020)
  • Table 109. Africa DTaP Vaccine , by Product Type USD Million (2015-2020)
  • Table 110. Africa DTaP Vaccine , by End User USD Million (2015-2020)
  • Table 111. North America DTaP Vaccine , by Country USD Million (2015-2020)
  • Table 112. North America DTaP Vaccine , by Type USD Million (2015-2020)
  • Table 113. North America DTaP Vaccine , by Application USD Million (2015-2020)
  • Table 114. North America DTaP Vaccine , by Product Type USD Million (2015-2020)
  • Table 115. North America DTaP Vaccine , by End User USD Million (2015-2020)
  • Table 116. United States DTaP Vaccine , by Type USD Million (2015-2020)
  • Table 117. United States DTaP Vaccine , by Application USD Million (2015-2020)
  • Table 118. United States DTaP Vaccine , by Product Type USD Million (2015-2020)
  • Table 119. United States DTaP Vaccine , by End User USD Million (2015-2020)
  • Table 120. Canada DTaP Vaccine , by Type USD Million (2015-2020)
  • Table 121. Canada DTaP Vaccine , by Application USD Million (2015-2020)
  • Table 122. Canada DTaP Vaccine , by Product Type USD Million (2015-2020)
  • Table 123. Canada DTaP Vaccine , by End User USD Million (2015-2020)
  • Table 124. Mexico DTaP Vaccine , by Type USD Million (2015-2020)
  • Table 125. Mexico DTaP Vaccine , by Application USD Million (2015-2020)
  • Table 126. Mexico DTaP Vaccine , by Product Type USD Million (2015-2020)
  • Table 127. Mexico DTaP Vaccine , by End User USD Million (2015-2020)
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. DTaP Vaccine : by Type(USD Million)
  • Table 139. DTaP Vaccine  Diphtheria , by Region USD Million (2021-2026)
  • Table 140. DTaP Vaccine  Tetanus , by Region USD Million (2021-2026)
  • Table 141. DTaP Vaccine  Pertussis , by Region USD Million (2021-2026)
  • Table 142. DTaP Vaccine : by Application(USD Million)
  • Table 143. DTaP Vaccine  Adult , by Region USD Million (2021-2026)
  • Table 144. DTaP Vaccine  Pediatric , by Region USD Million (2021-2026)
  • Table 145. DTaP Vaccine : by Type(USD Million)
  • Table 146. DTaP Vaccine  Diphtheria , by Region USD Million (2021-2026)
  • Table 147. DTaP Vaccine  Tetanus , by Region USD Million (2021-2026)
  • Table 148. DTaP Vaccine  Pertussis , by Region USD Million (2021-2026)
  • Table 149. DTaP Vaccine : by Product Type(USD Million)
  • Table 150. DTaP Vaccine  Generic Drug , by Region USD Million (2021-2026)
  • Table 151. DTaP Vaccine  Branded Drug , by Region USD Million (2021-2026)
  • Table 152. DTaP Vaccine : by End User(USD Million)
  • Table 153. DTaP Vaccine  Hospitals , by Region USD Million (2021-2026)
  • Table 154. DTaP Vaccine  Clinics , by Region USD Million (2021-2026)
  • Table 155. DTaP Vaccine  Vaccination Centers , by Region USD Million (2021-2026)
  • Table 156. South America DTaP Vaccine , by Country USD Million (2021-2026)
  • Table 157. South America DTaP Vaccine , by Type USD Million (2021-2026)
  • Table 158. South America DTaP Vaccine , by Application USD Million (2021-2026)
  • Table 159. South America DTaP Vaccine , by Product Type USD Million (2021-2026)
  • Table 160. South America DTaP Vaccine , by End User USD Million (2021-2026)
  • Table 161. Brazil DTaP Vaccine , by Type USD Million (2021-2026)
  • Table 162. Brazil DTaP Vaccine , by Application USD Million (2021-2026)
  • Table 163. Brazil DTaP Vaccine , by Product Type USD Million (2021-2026)
  • Table 164. Brazil DTaP Vaccine , by End User USD Million (2021-2026)
  • Table 165. Argentina DTaP Vaccine , by Type USD Million (2021-2026)
  • Table 166. Argentina DTaP Vaccine , by Application USD Million (2021-2026)
  • Table 167. Argentina DTaP Vaccine , by Product Type USD Million (2021-2026)
  • Table 168. Argentina DTaP Vaccine , by End User USD Million (2021-2026)
  • Table 169. Rest of South America DTaP Vaccine , by Type USD Million (2021-2026)
  • Table 170. Rest of South America DTaP Vaccine , by Application USD Million (2021-2026)
  • Table 171. Rest of South America DTaP Vaccine , by Product Type USD Million (2021-2026)
  • Table 172. Rest of South America DTaP Vaccine , by End User USD Million (2021-2026)
  • Table 173. Asia Pacific DTaP Vaccine , by Country USD Million (2021-2026)
  • Table 174. Asia Pacific DTaP Vaccine , by Type USD Million (2021-2026)
  • Table 175. Asia Pacific DTaP Vaccine , by Application USD Million (2021-2026)
  • Table 176. Asia Pacific DTaP Vaccine , by Product Type USD Million (2021-2026)
  • Table 177. Asia Pacific DTaP Vaccine , by End User USD Million (2021-2026)
  • Table 178. China DTaP Vaccine , by Type USD Million (2021-2026)
  • Table 179. China DTaP Vaccine , by Application USD Million (2021-2026)
  • Table 180. China DTaP Vaccine , by Product Type USD Million (2021-2026)
  • Table 181. China DTaP Vaccine , by End User USD Million (2021-2026)
  • Table 182. Japan DTaP Vaccine , by Type USD Million (2021-2026)
  • Table 183. Japan DTaP Vaccine , by Application USD Million (2021-2026)
  • Table 184. Japan DTaP Vaccine , by Product Type USD Million (2021-2026)
  • Table 185. Japan DTaP Vaccine , by End User USD Million (2021-2026)
  • Table 186. India DTaP Vaccine , by Type USD Million (2021-2026)
  • Table 187. India DTaP Vaccine , by Application USD Million (2021-2026)
  • Table 188. India DTaP Vaccine , by Product Type USD Million (2021-2026)
  • Table 189. India DTaP Vaccine , by End User USD Million (2021-2026)
  • Table 190. South Korea DTaP Vaccine , by Type USD Million (2021-2026)
  • Table 191. South Korea DTaP Vaccine , by Application USD Million (2021-2026)
  • Table 192. South Korea DTaP Vaccine , by Product Type USD Million (2021-2026)
  • Table 193. South Korea DTaP Vaccine , by End User USD Million (2021-2026)
  • Table 194. Taiwan DTaP Vaccine , by Type USD Million (2021-2026)
  • Table 195. Taiwan DTaP Vaccine , by Application USD Million (2021-2026)
  • Table 196. Taiwan DTaP Vaccine , by Product Type USD Million (2021-2026)
  • Table 197. Taiwan DTaP Vaccine , by End User USD Million (2021-2026)
  • Table 198. Australia DTaP Vaccine , by Type USD Million (2021-2026)
  • Table 199. Australia DTaP Vaccine , by Application USD Million (2021-2026)
  • Table 200. Australia DTaP Vaccine , by Product Type USD Million (2021-2026)
  • Table 201. Australia DTaP Vaccine , by End User USD Million (2021-2026)
  • Table 202. Rest of Asia-Pacific DTaP Vaccine , by Type USD Million (2021-2026)
  • Table 203. Rest of Asia-Pacific DTaP Vaccine , by Application USD Million (2021-2026)
  • Table 204. Rest of Asia-Pacific DTaP Vaccine , by Product Type USD Million (2021-2026)
  • Table 205. Rest of Asia-Pacific DTaP Vaccine , by End User USD Million (2021-2026)
  • Table 206. Europe DTaP Vaccine , by Country USD Million (2021-2026)
  • Table 207. Europe DTaP Vaccine , by Type USD Million (2021-2026)
  • Table 208. Europe DTaP Vaccine , by Application USD Million (2021-2026)
  • Table 209. Europe DTaP Vaccine , by Product Type USD Million (2021-2026)
  • Table 210. Europe DTaP Vaccine , by End User USD Million (2021-2026)
  • Table 211. Germany DTaP Vaccine , by Type USD Million (2021-2026)
  • Table 212. Germany DTaP Vaccine , by Application USD Million (2021-2026)
  • Table 213. Germany DTaP Vaccine , by Product Type USD Million (2021-2026)
  • Table 214. Germany DTaP Vaccine , by End User USD Million (2021-2026)
  • Table 215. France DTaP Vaccine , by Type USD Million (2021-2026)
  • Table 216. France DTaP Vaccine , by Application USD Million (2021-2026)
  • Table 217. France DTaP Vaccine , by Product Type USD Million (2021-2026)
  • Table 218. France DTaP Vaccine , by End User USD Million (2021-2026)
  • Table 219. Italy DTaP Vaccine , by Type USD Million (2021-2026)
  • Table 220. Italy DTaP Vaccine , by Application USD Million (2021-2026)
  • Table 221. Italy DTaP Vaccine , by Product Type USD Million (2021-2026)
  • Table 222. Italy DTaP Vaccine , by End User USD Million (2021-2026)
  • Table 223. United Kingdom DTaP Vaccine , by Type USD Million (2021-2026)
  • Table 224. United Kingdom DTaP Vaccine , by Application USD Million (2021-2026)
  • Table 225. United Kingdom DTaP Vaccine , by Product Type USD Million (2021-2026)
  • Table 226. United Kingdom DTaP Vaccine , by End User USD Million (2021-2026)
  • Table 227. Netherlands DTaP Vaccine , by Type USD Million (2021-2026)
  • Table 228. Netherlands DTaP Vaccine , by Application USD Million (2021-2026)
  • Table 229. Netherlands DTaP Vaccine , by Product Type USD Million (2021-2026)
  • Table 230. Netherlands DTaP Vaccine , by End User USD Million (2021-2026)
  • Table 231. Rest of Europe DTaP Vaccine , by Type USD Million (2021-2026)
  • Table 232. Rest of Europe DTaP Vaccine , by Application USD Million (2021-2026)
  • Table 233. Rest of Europe DTaP Vaccine , by Product Type USD Million (2021-2026)
  • Table 234. Rest of Europe DTaP Vaccine , by End User USD Million (2021-2026)
  • Table 235. MEA DTaP Vaccine , by Country USD Million (2021-2026)
  • Table 236. MEA DTaP Vaccine , by Type USD Million (2021-2026)
  • Table 237. MEA DTaP Vaccine , by Application USD Million (2021-2026)
  • Table 238. MEA DTaP Vaccine , by Product Type USD Million (2021-2026)
  • Table 239. MEA DTaP Vaccine , by End User USD Million (2021-2026)
  • Table 240. Middle East DTaP Vaccine , by Type USD Million (2021-2026)
  • Table 241. Middle East DTaP Vaccine , by Application USD Million (2021-2026)
  • Table 242. Middle East DTaP Vaccine , by Product Type USD Million (2021-2026)
  • Table 243. Middle East DTaP Vaccine , by End User USD Million (2021-2026)
  • Table 244. Africa DTaP Vaccine , by Type USD Million (2021-2026)
  • Table 245. Africa DTaP Vaccine , by Application USD Million (2021-2026)
  • Table 246. Africa DTaP Vaccine , by Product Type USD Million (2021-2026)
  • Table 247. Africa DTaP Vaccine , by End User USD Million (2021-2026)
  • Table 248. North America DTaP Vaccine , by Country USD Million (2021-2026)
  • Table 249. North America DTaP Vaccine , by Type USD Million (2021-2026)
  • Table 250. North America DTaP Vaccine , by Application USD Million (2021-2026)
  • Table 251. North America DTaP Vaccine , by Product Type USD Million (2021-2026)
  • Table 252. North America DTaP Vaccine , by End User USD Million (2021-2026)
  • Table 253. United States DTaP Vaccine , by Type USD Million (2021-2026)
  • Table 254. United States DTaP Vaccine , by Application USD Million (2021-2026)
  • Table 255. United States DTaP Vaccine , by Product Type USD Million (2021-2026)
  • Table 256. United States DTaP Vaccine , by End User USD Million (2021-2026)
  • Table 257. Canada DTaP Vaccine , by Type USD Million (2021-2026)
  • Table 258. Canada DTaP Vaccine , by Application USD Million (2021-2026)
  • Table 259. Canada DTaP Vaccine , by Product Type USD Million (2021-2026)
  • Table 260. Canada DTaP Vaccine , by End User USD Million (2021-2026)
  • Table 261. Mexico DTaP Vaccine , by Type USD Million (2021-2026)
  • Table 262. Mexico DTaP Vaccine , by Application USD Million (2021-2026)
  • Table 263. Mexico DTaP Vaccine , by Product Type USD Million (2021-2026)
  • Table 264. Mexico DTaP Vaccine , by End User USD Million (2021-2026)
  • Table 265. Research Programs/Design for This Report
  • Table 266. Key Data Information from Secondary Sources
  • Table 267. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global DTaP Vaccine : by Type USD Million (2015-2020)
  • Figure 5. Global DTaP Vaccine : by Application USD Million (2015-2020)
  • Figure 6. Global DTaP Vaccine : by Type USD Million (2015-2020)
  • Figure 7. Global DTaP Vaccine : by Product Type USD Million (2015-2020)
  • Figure 8. Global DTaP Vaccine : by End User USD Million (2015-2020)
  • Figure 9. South America DTaP Vaccine  Share (%), by Country
  • Figure 10. Asia Pacific DTaP Vaccine  Share (%), by Country
  • Figure 11. Europe DTaP Vaccine  Share (%), by Country
  • Figure 12. MEA DTaP Vaccine  Share (%), by Country
  • Figure 13. North America DTaP Vaccine  Share (%), by Country
  • Figure 14. Global DTaP Vaccine  share by Players 2020 (%)
  • Figure 15. Global DTaP Vaccine  share by Players (Top 3) 2020(%)
  • Figure 16. Global DTaP Vaccine  share by Players (Top 5) 2020(%)
  • Figure 17. BCG Matrix for key Companies
  • Figure 18. GlaxoSmithKline plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 19. GlaxoSmithKline plc (United Kingdom) Revenue: by Geography 2020
  • Figure 20. Sanofi (France) Revenue, Net Income and Gross profit
  • Figure 21. Sanofi (France) Revenue: by Geography 2020
  • Figure 22. Novartis International AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 23. Novartis International AG (Switzerland) Revenue: by Geography 2020
  • Figure 24. Merck (Germany) Revenue, Net Income and Gross profit
  • Figure 25. Merck (Germany) Revenue: by Geography 2020
  • Figure 26. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 27. Pfizer Inc. (United States) Revenue: by Geography 2020
  • Figure 28. Astellas Pharma Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 29. Astellas Pharma Inc. (United States) Revenue: by Geography 2020
  • Figure 30. Emergent BioSolutions Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 31. Emergent BioSolutions Inc. (United States) Revenue: by Geography 2020
  • Figure 32. AstraZeneca plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 33. AstraZeneca plc (United Kingdom) Revenue: by Geography 2020
  • Figure 34. Serum Institute Of India (India) Revenue, Net Income and Gross profit
  • Figure 35. Serum Institute Of India (India) Revenue: by Geography 2020
  • Figure 36. Grifols, S.A.(Spain) Revenue, Net Income and Gross profit
  • Figure 37. Grifols, S.A.(Spain) Revenue: by Geography 2020
  • Figure 38. Global DTaP Vaccine : by Type USD Million (2021-2026)
  • Figure 39. Global DTaP Vaccine : by Application USD Million (2021-2026)
  • Figure 40. Global DTaP Vaccine : by Type USD Million (2021-2026)
  • Figure 41. Global DTaP Vaccine : by Product Type USD Million (2021-2026)
  • Figure 42. Global DTaP Vaccine : by End User USD Million (2021-2026)
  • Figure 43. South America DTaP Vaccine  Share (%), by Country
  • Figure 44. Asia Pacific DTaP Vaccine  Share (%), by Country
  • Figure 45. Europe DTaP Vaccine  Share (%), by Country
  • Figure 46. MEA DTaP Vaccine  Share (%), by Country
  • Figure 47. North America DTaP Vaccine  Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • GlaxoSmithKline plc (United Kingdom)
  • Sanofi (France)
  • Novartis International AG (Switzerland)
  • Merck (Germany)
  • Pfizer Inc. (United States)
  • Astellas Pharma Inc. (United States)
  • Emergent BioSolutions Inc. (United States)
  • AstraZeneca plc (United Kingdom)
  • Serum Institute Of India (India)
  • Grifols, S.A.(Spain)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation